The road to an FDA nod for Coherus BioSciences’ China-made PD-1 inhibitor has been long and tortuous. After a complete response letter and delayed preapproval inspections, the FDA found a fresh ...

Udenyca Onbody is expected to be available in the first quarter of 2024 and will be supplied in a carton containing 1 on-body injector co-packaged with 1 prefilled syringe. The Food and Drug ...

Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...

The Food and Drug Administration approved Udenyca Onbody, an administration device for Udenyca, a biosimilar of Neulasta. The Food and Drug Administration (FDA) approved Udenyca Onbody, an injector ...

Neulasta (pegfilgrastim) is a prescription drug used to prevent infection from certain cancer therapy and to treat radiation sickness. Neulasta’s cost may depend on factors such as your dosage and the ...

Coherus BioSciences, Inc. CHRS shares were up 8.1% on Friday after the company announced that it has resubmitted the biologics license application (BLA) supplement for Udenyca Onbody to the FDA.

Before you start treatment with Neulasta, tell your doctor and pharmacist which prescription, over-the-counter, and other medications you take. By sharing this information with them, you may help ...

The approval was based on a review of a comprehensive data package and a totality of evidence demonstrating a high degree of similarity of Stimufend to the reference product. Stimufend, a leukocyte ...

Improving advanced directive completion rates on an inpatient oncology unit using internal medicine resident participation: A quality improvement study.